Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 192.81M P/E - EPS this Y -14.30% Ern Qtrly Grth -
Income -10.68M Forward P/E 12.03 EPS next Y 25.00% 50D Avg Chg -17.00%
Sales 101.12M PEG 2.22 EPS past 5Y -14.78% 200D Avg Chg 18.00%
Dividend N/A Price/Book 2.59 EPS next 5Y 10.00% 52W High Chg -27.00%
Recommedations 2.00 Quick Ratio 0.73 Shares Outstanding 43.61M 52W Low Chg 131.00%
Insider Own 7.77% ROA -1.62% Shares Float 38.22M Beta 1.30
Inst Own 73.70% ROE -14.97% Shares Shorted/Prior 429.12K/426.79K Price 4.57
Gross Margin 58.70% Profit Margin -10.56% Avg. Volume 298,627 Target Price 6.25
Oper. Margin -7.24% Earnings Date Nov 5 Volume 169,779 Change 1.11%
About Harvard Bioscience, Inc.

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

Harvard Bioscience, Inc. News
11/09/24 Harvard Bioscience Third Quarter 2024 Earnings: Misses Expectations
11/08/24 Harvard Bioscience Inc (HBIO) Q3 2024 Earnings Call Highlights: Navigating Challenges and ...
11/07/24 3 Promising US Penny Stocks With At Least $100M Market Cap
11/07/24 Harvard Bioscience: Q3 Earnings Snapshot
11/07/24 Harvard Bioscience Announces Third Quarter 2024 Financial Results
11/01/24 Is It Too Late To Consider Buying Harvard Bioscience, Inc. (NASDAQ:HBIO)?
10/31/24 Zacks Industry Outlook Highlights Mettler-Toledo International and Harvard Bioscience
10/29/24 Harvard Bioscience Schedules Third Quarter 2024 Earnings Conference Call for November 7, 2024 at 8:00 AM ET
10/09/24 Harvard Bioscience Inc (HBIO) Q2 2024 Earnings Call Highlights: Navigating Challenges with ...
10/03/24 Harvard Bioscience to Showcase Innovative Technologies at Society for Neuroscience (SfN) Annual Meeting 2024
09/28/24 The past three years for Harvard Bioscience (NASDAQ:HBIO) investors has not been profitable
09/18/24 Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Safety Pharmacology Society Annual Meeting
09/17/24 Sidoti Events, LLC's Virtual September Small-Cap Conference
09/05/24 Harvard Bioscience, Inc. to Participate in the Sidoti Small Cap Virtual Conference
09/01/24 Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Could Be 50% Below Their Intrinsic Value Estimate
08/11/24 Some Analysts Just Cut Their Harvard Bioscience, Inc. (NASDAQ:HBIO) Estimates
08/08/24 Harvard Bioscience: Q2 Earnings Snapshot
08/08/24 Harvard Bioscience Announces Second Quarter 2024 Financial Results
08/07/24 Institutional investors may adopt severe steps after Harvard Bioscience, Inc.'s (NASDAQ:HBIO) latest 13% drop adds to a year losses
08/02/24 Harvard Bioscience Schedules Second Quarter 2024 Earnings Conference Call for August 8, 2024 at 10:00 AM ET
HBIO Chatroom

User Image LiarsPoker13 Posted - 2 days ago

$HBIO this stock is cheap. baseline revenue of 22M and profitable is derisked. As organoids ramps, this is a great buy; revenue has stabilized and is returning to growth

User Image PenkeTrading Posted - 1 week ago

I found you a Three Black Crows Candle Pattern on the daily chart of Harvard Bioscience Inc. $HBIO #ThreeBlackCrows #NASDAQ

User Image WeeklyTrader Posted - 1 month ago

Time to rethink $HBIO! RSI: 42.82% 50-day MA: $2.77 200-day MA: $3.6

User Image TheLearnerEarner Posted - 1 month ago

$HBIO ✅ UNDERVALUED stock swing trade - healthcare - small cap - 5/9 F-Score - 1.8x relative volume - 3x analysts buy rating - trading at 56.7% below estimate of its fair value - short to medium term gains 📈 RSI: 35.19 (oversold bullish) 📊🐂 Analyst Price Target: $6.25 - $7.35 (160.42% - 202.47% above Price) 🌟 Range (12m) $2.39 - $5.56 💰 NEWSDESK (last recent article) 📰 https://www.stocktitan.net/news/HBIO/harvard-bioscience-to-showcase-innovative-technologies-at-society-fds9ng64nqgp.html

User Image FinJay Posted - 09/24/24

$HBIO https://youtu.be/gfmiNCHj_J0?si=5qrwgVzgnYTpACCI

User Image Stock_Titan Posted - 2 months ago

$HBIO Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Safety Pharmacology Society Annual Meeting https://www.stocktitan.net/news/HBIO/harvard-bioscience-to-showcase-latest-solutions-for-preclinical-and-ev30ryw0zwmr.html

User Image kinderspiel Posted - 3 months ago

Aug 15 volume of shares traded $NTLA 514.3 k $AVXL 277.7 k $TARS 222.8 k $HBIO 107.2 k $XBIT 8.0 k

User Image epsguid Posted - 3 months ago

$HBIO reported a loss of $0.03, consensus was $0.03 via @eWhispers #epsmiss http://eps.sh/d/hbio

User Image Stock_Titan Posted - 3 months ago

$HBIO Harvard Bioscience Announces Second Quarter 2024 Financial Results https://www.stocktitan.net/news/HBIO/harvard-bioscience-announces-second-quarter-2024-financial-y5p3yqxz0tok.html

User Image Stock_Titan Posted - 3 months ago

$HBIO Harvard Bioscience Schedules Second Quarter 2024 Earnings Conference Call for August 8, 2024 at 10:00 AM ET https://www.stocktitan.net/news/HBIO/harvard-bioscience-schedules-second-quarter-2024-earnings-conference-t2r9w9jxno9c.html

User Image NVDAMillionaire Posted - 07/30/24

$HBIO Harvard Bioscience, Inc. (NASDAQ:HBIO): Navigating Headwinds with Innovative Solutions http://beyondspx.com/2024/07/30/harvard-bioscience-inc-nasdaqhbio-navigating-headwinds-with-innovative-solutions/

User Image RealAvidTrader Posted - 4 months ago

$CTXR $HBIO $DHAI 💣 MASSIVE Catalysts Ahead For This Undervalued Biotech Penny Stock 💣 https://youtu.be/-U0rA3hnTFk

User Image NVDAMillionaire Posted - 4 months ago

$HBIO Harvard Bioscience, Inc. (NASDAQ:HBIO) Q1 2024 Earnings Review: Navigating Headwinds and Positioning for Growth http://beyondspx.com/2024/07/11/harvard-bioscience-inc-nasdaqhbio-q1-2024-earnings-review-navigating-headwinds-and-positioning-for-growth/

User Image Capes Posted - 4 months ago

$SGMO $LCFY $SNTG $IGMS $HBIO

User Image richardred Posted - 4 months ago

$HBIO Glad I bought some at the 52 week low. Sold those shares today for a nice gain.

User Image richardred Posted - 5 months ago

$HBIO I might be a bit early, but I’m adding in here. I wonder what they’re gonna talk about at the schedule conference next week?

User Image TheLearnerEarner Posted - 5 months ago

$HBIO added UNDERVALUED stock swing trade - healthcare - small cap - 6/9 F-Score - 5.3x relative volume - Keybanc overweight rating - 2x analysts buy rating - earnings are forecast to grow 106.71% per year - trading at 51.8% below estimate of its fair value - short to medium term gains 📈 Unusual Volume Activity 🚀 RSI: 22.09 (oversold) 📊 Analyst Price Target: $6.75 - $7.00 (132.76% - 141.38% above Price) 🌟 Range (12m) $2.92 - $6.20 💰 NEWSDESK (last recent article) 📰 https://www.stocktitan.net/news/HBIO/harvard-bioscience-inc-to-present-and-host-one-on-one-meetings-at-5okcgmf8vwq7.html

User Image richardred Posted - 5 months ago

$HBIO Big green candle on huge volume. 460,000 shares someone’s buying. Yet someone’s selling .

User Image CEOBuysDisclosures Posted - 5 months ago

$HBIO CEO purchased 20,000 shares at $3.07 for a total of $61,400. Green James W now owns 3,101,091 shares. https://ceo-buys.com

User Image richardred Posted - 5 months ago

$HBIO I’m buying down here. Heck I’d think Mr. Green might join me soon?

User Image LiarsPoker13 Posted - 05/25/24

$HBIO getting attractive down here all they need is rev growth and with these margins its 8+ the organoid potential is extraordinary

User Image epsguid Posted - 6 months ago

$HBIO reported $0.00, consensus was $0.00 via @eWhispers #epsmeet http://eps.sh/d/hbio

User Image DonCorleone77 Posted - 6 months ago

$HBIO Harvard Bioscience reports Q1 adjusted EPS 2c, consensus 2c Reports Q1 revenue $24.5M, consensus $25.79M. Jim Green, Chairman and CEO, said, "As expected, our first quarter revenues reflect ongoing market headwinds, especially in APAC, amplified by a strong prior year comparison. Despite these headwinds, we were pleased to deliver gross margins of 60%. After quarter end, we announced a cost reduction initiative to improve our operating cost structure and support our ongoing investments in growth. Looking ahead, we are excited by our growth strategy and new product commercializations. Together with the new round of Chinese stimulus targeting a range of products including academic research and healthcare products, we continue to expect solid growth in the second half."

User Image Stock_Titan Posted - 6 months ago

$HBIO Harvard Bioscience Announces First Quarter 2024 Financial Results https://www.stocktitan.net/news/HBIO/harvard-bioscience-announces-first-quarter-2024-financial-pikvpcrlf9hu.html

User Image Stock_Titan Posted - 04/29/24

$HBIO Harvard Bioscience Schedules First Quarter 2024 Earnings Conference Call for May 7, 2024 at 8:00 AM ET https://www.stocktitan.net/news/HBIO/harvard-bioscience-schedules-first-quarter-2024-earnings-conference-eobf090rwh8r.html

User Image DonCorleone77 Posted - 7 months ago

$HBIO Harvard Bioscience announces labor force reduction to improve cost structure Harvard Bioscience announced a labor force reduction to improve its operating cost structure and support its ongoing investments in growth. The Company expects to realize overall annual run rate savings of approximately $4 million beginning in the second quarter of 2024. The Company also expects second quarter restructuring-related charges of approximately $0.5 million. Jim Green, Harvard Bioscience Chairman and CEO, said, "We remain focused on organizational efficiencies and aligning our global operating structure with our strategic growth priorities. This action is intended to underpin our financial performance while we continue to focus on our growth initiatives."

User Image Stock_Titan Posted - 7 months ago

$HBIO Harvard Bioscience Announces Action to Improve Operational Efficiency and Support Ongoing Investments in Growth https://www.stocktitan.net/news/HBIO/harvard-bioscience-announces-action-to-improve-operational-9du5g8eek8ni.html

User Image richardred Posted - 8 months ago

$HBIO Looks like a possible fund dump @ EOD. 100,000 Red candle.

User Image Stock_Titan Posted - 8 months ago

$HBIO Harvard Bioscience, Inc. to Participate in March 2024 Investor Conferences: Sidoti’s Small Cap Conference and KeyBanc’s Life Sciences & MedTech Conference https://www.stocktitan.net/news/HBIO/harvard-bioscience-inc-to-participate-in-march-2024-investor-fasmjdlr0ynv.html

User Image epsguid Posted - 8 months ago

$HBIO reported earnings of $0.01, consensus was $0.03 via @eWhispers #epsmiss http://eps.sh/d/hbio

Analyst Ratings
Benchmark Speculative Buy Jun 22, 23
Benchmark Buy Apr 26, 23
Keybanc Overweight Apr 26, 23
Benchmark Buy Mar 10, 23
Keybanc Overweight Nov 9, 22
Keybanc Overweight Aug 5, 22
Keybanc Overweight Nov 10, 20
Benchmark Speculative Buy Feb 27, 20
Singular Research Buy Nov 17, 16
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Green James W Chief Executive Offi.. Chief Executive Officer Mar 14 Buy 2.64 40,000 105,600 2,886,052 03/15/23
LOY BERTRAND Director Director Aug 26 Buy 3.41 9,291 31,682 399,651 08/29/22
LOY BERTRAND Director Director Aug 18 Buy 3.24 10,759 34,859 350,968 08/22/22
Green James W Chief Executive Offi.. Chief Executive Officer May 06 Buy 3.59 40,000 143,600 2,319,955 05/10/22
Green James W Chief Executive Offi.. Chief Executive Officer May 19 Option 2.63 39,188 103,064 2,318,966 05/19/21